GlassScriptPhysician profile
Megan E Brown
NPI 1821389180
$2,240.99
in general payments reported to CMS, 2019-2025
27 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $249 · 2021: $527 · 2022: $261 · 2023: $113 · 2024: $129 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $330.11 | 2019-2025 | |
| Novo Nordisk INC | $325.80 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $240.33 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $239.82 | 2019-2024 | Dalvance |
| Novartis Pharmaceuticals Corporation | $172.16 | 2019-2025 | |
| Pacira Pharmaceuticals Incorporated | $93.29 | 2021 | |
| Corcept Therapeutics | $85.96 | 2025 | Korlym |
| Lilly USA, LLC | $75.63 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $67.38 | 2021-2025 | Pediarix, Penmenvy, Bexsero |
| Grifols USA, LLC | $63.17 | 2019-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $62.69 | 2021-2023 | Steglatro, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $45.55 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $44.95 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $43.64 | 2019 | |
| Electromed, INC. | $40.02 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $39.39 | 2020-2021 | |
| Therapeuticsmd, INC. | $37.59 | 2019-2020 | |
| Eisai INC. | $36.70 | 2021 | |
| Amarin Pharma, INC. | $29.50 | 2020-2021 | |
| Vapotherm INC | $29.41 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.23 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $22.48 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $21.69 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.40 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.88 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.66 | 2019 | |
| Axsome Therapeutics, INC. | $13.56 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.